Levodopa gains psychostimulant‐like properties after nigral dopaminergic loss
Identifieur interne : 000E64 ( Main/Exploration ); précédent : 000E63; suivant : 000E65Levodopa gains psychostimulant‐like properties after nigral dopaminergic loss
Auteurs : Michel Engeln [France] ; Stefania Fasano [Italie] ; Serge H. Ahmed [France] ; Martine Cador [France] ; Veerle Baekelandt [Belgique] ; Erwan Bezard [France] ; Pierre-Olivier Fernagut [France]Source :
- Annals of Neurology [ 0364-5134 ] ; 2013-07.
English descriptors
- KwdEn :
- Adenoviridae (genetics), Adenoviridae (metabolism), Animals, Antiparkinson Agents (pharmacology), Antiparkinson Agents (therapeutic use), Conditioning, Operant (drug effects), Conditioning, Operant (physiology), Disease Models, Animal, Dopaminergic Neurons (drug effects), Dopaminergic Neurons (pathology), Food Preferences (drug effects), Humans, Levodopa (pharmacology), Levodopa (therapeutic use), Male, Mutation (genetics), Parkinson Disease (drug therapy), Parkinson Disease (etiology), Parkinson Disease (genetics), Parkinson Disease (pathology), Rats, Rats, Wistar, Reward, Saccharin (administration & dosage), Substantia Nigra (pathology), Sweetening Agents (administration & dosage), Taste (drug effects), Transduction, Genetic, Tyrosine 3-Monooxygenase (metabolism), Ubiquitin (metabolism), alpha-Synuclein (genetics), alpha-Synuclein (toxicity).
- MESH :
- chemical , administration & dosage : Saccharin, Sweetening Agents.
- chemical , genetics : alpha-Synuclein.
- chemical , metabolism : Tyrosine 3-Monooxygenase, Ubiquitin.
- chemical , pharmacology : Antiparkinson Agents, Levodopa.
- drug effects : Conditioning, Operant, Dopaminergic Neurons, Food Preferences, Taste.
- drug therapy : Parkinson Disease.
- etiology : Parkinson Disease.
- genetics : Adenoviridae, Mutation, Parkinson Disease.
- metabolism : Adenoviridae.
- pathology : Dopaminergic Neurons, Parkinson Disease, Substantia Nigra.
- physiology : Conditioning, Operant.
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- chemical , toxicity : alpha-Synuclein.
- Animals, Disease Models, Animal, Humans, Male, Rats, Rats, Wistar, Reward, Transduction, Genetic.
Abstract
Dopamine dysregulation syndrome shares some core behavioral features with psychostimulant addiction, suggesting that dopamine replacement therapy can acquire psychostimulantlike properties in some patients with Parkinson disease (PD). We here report strong experimental evidence supporting this hypothesis in an α‐synuclein rat model of PD. Although levodopa had no effect in controls, it acquired 2 prominent psychostimulantlike properties in Parkinsonian rats: (1) it produced intense reward on its own and in parallel (2) decreased interest in other nondrug reward. These 2 effects may combine to explain the addictive use of levodopa after loss of midbrain dopamine neurons in some PD patients. Ann Neurol 2013;74:140–144
Url:
- https://api.istex.fr/document/83FE1078C36E1437D794AE68D5AEC6C76421ABFC/fulltext/pdf
- https://hal.archives-ouvertes.fr/hal-01153692
DOI: 10.1002/ana.23881
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000648
- to stream Istex, to step Curation: 000648
- to stream Istex, to step Checkpoint: 000071
- to stream PubMed, to step Corpus: 000711
- to stream PubMed, to step Curation: 000680
- to stream PubMed, to step Checkpoint: 000680
- to stream Ncbi, to step Merge: 001100
- to stream Ncbi, to step Curation: 001100
- to stream Ncbi, to step Checkpoint: 001100
- to stream Main, to step Merge: 000E92
- to stream Hal, to step Corpus: 000629
- to stream Hal, to step Curation: 000629
- to stream Hal, to step Checkpoint: 000355
- to stream Main, to step Merge: 000B69
- to stream Main, to step Curation: 000E64
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Levodopa gains psychostimulant‐like properties after nigral dopaminergic loss</title><author><name sortKey="Engeln, Michel" sort="Engeln, Michel" uniqKey="Engeln M" first="Michel" last="Engeln">Michel Engeln</name></author><author><name sortKey="Fasano, Stefania" sort="Fasano, Stefania" uniqKey="Fasano S" first="Stefania" last="Fasano">Stefania Fasano</name></author><author><name sortKey="Ahmed, Serge H" sort="Ahmed, Serge H" uniqKey="Ahmed S" first="Serge H." last="Ahmed">Serge H. Ahmed</name></author><author><name sortKey="Cador, Martine" sort="Cador, Martine" uniqKey="Cador M" first="Martine" last="Cador">Martine Cador</name></author><author><name sortKey="Baekelandt, Veerle" sort="Baekelandt, Veerle" uniqKey="Baekelandt V" first="Veerle" last="Baekelandt">Veerle Baekelandt</name></author><author><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bezard">Erwan Bezard</name></author><author><name sortKey="Fernagut, Pierre Livier" sort="Fernagut, Pierre Livier" uniqKey="Fernagut P" first="Pierre-Olivier" last="Fernagut">Pierre-Olivier Fernagut</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:83FE1078C36E1437D794AE68D5AEC6C76421ABFC</idno><date when="2013" year="2013">2013</date><idno type="doi">10.1002/ana.23881</idno><idno type="url">https://api.istex.fr/document/83FE1078C36E1437D794AE68D5AEC6C76421ABFC/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000648</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000648</idno><idno type="wicri:Area/Istex/Curation">000648</idno><idno type="wicri:Area/Istex/Checkpoint">000071</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000071</idno><idno type="wicri:doubleKey">0364-5134:2013:Engeln M:levodopa:gains:psychostimulant</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:23494678</idno><idno type="wicri:Area/PubMed/Corpus">000711</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000711</idno><idno type="wicri:Area/PubMed/Curation">000680</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000680</idno><idno type="wicri:Area/PubMed/Checkpoint">000680</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000680</idno><idno type="wicri:Area/Ncbi/Merge">001100</idno><idno type="wicri:Area/Ncbi/Curation">001100</idno><idno type="wicri:Area/Ncbi/Checkpoint">001100</idno><idno type="wicri:Area/Main/Merge">000E92</idno><idno type="wicri:source">HAL</idno><idno type="RBID">Hal:hal-01153692</idno><idno type="url">https://hal.archives-ouvertes.fr/hal-01153692</idno><idno type="wicri:Area/Hal/Corpus">000629</idno><idno type="wicri:Area/Hal/Curation">000629</idno><idno type="wicri:Area/Hal/Checkpoint">000355</idno><idno type="wicri:explorRef" wicri:stream="Hal" wicri:step="Checkpoint">000355</idno><idno type="wicri:doubleKey">0364-5134:2013:Engeln M:levodopa:gains:psychostimulant</idno><idno type="wicri:Area/Main/Merge">000B69</idno><idno type="wicri:Area/Main/Curation">000E64</idno><idno type="wicri:Area/Main/Exploration">000E64</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Levodopa gains psychostimulant‐like properties after nigral dopaminergic loss</title><author><name sortKey="Engeln, Michel" sort="Engeln, Michel" uniqKey="Engeln M" first="Michel" last="Engeln">Michel Engeln</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Institute of Neurodegenerative Diseases, UMR 5293, F‐33000 Bordeaux, France, University of Bordeaux, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Institute of Neurodegenerative Diseases, UMR 5293, F‐33000 Bordeaux, France, National Center for Scientific Research, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Fasano, Stefania" sort="Fasano, Stefania" uniqKey="Fasano S" first="Stefania" last="Fasano">Stefania Fasano</name><affiliation wicri:level="3"><country xml:lang="fr">Italie</country><wicri:regionArea>Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Research Institute, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Ahmed, Serge H" sort="Ahmed, Serge H" uniqKey="Ahmed S" first="Serge H." last="Ahmed">Serge H. Ahmed</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Institute of Neurodegenerative Diseases, UMR 5293, F‐33000 Bordeaux, France, University of Bordeaux, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Institute of Neurodegenerative Diseases, UMR 5293, F‐33000 Bordeaux, France, National Center for Scientific Research, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Cador, Martine" sort="Cador, Martine" uniqKey="Cador M" first="Martine" last="Cador">Martine Cador</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Aquitaine Institute of Cognitive and Integrative Neurosciences, University of Bordeaux, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Aquitaine Institute of Cognitive and Integrative Neurosciences, National Center for Scientific Research, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Baekelandt, Veerle" sort="Baekelandt, Veerle" uniqKey="Baekelandt V" first="Veerle" last="Baekelandt">Veerle Baekelandt</name><affiliation wicri:level="1"><country xml:lang="fr">Belgique</country><wicri:regionArea>Laboratory for Neurobiology and Gene Therapy, Catholic University, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bezard">Erwan Bezard</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Institute of Neurodegenerative Diseases, UMR 5293, F‐33000 Bordeaux, France, University of Bordeaux, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Institute of Neurodegenerative Diseases, UMR 5293, F‐33000 Bordeaux, France, National Center for Scientific Research, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Neurology Service, Bordeaux University Hospital Center, Pessac</wicri:regionArea><wicri:noRegion>Pessac</wicri:noRegion><wicri:noRegion>Pessac</wicri:noRegion></affiliation><affiliation wicri:level="1"><country wicri:rule="url">France</country></affiliation></author><author><name sortKey="Fernagut, Pierre Livier" sort="Fernagut, Pierre Livier" uniqKey="Fernagut P" first="Pierre-Olivier" last="Fernagut">Pierre-Olivier Fernagut</name><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Institute of Neurodegenerative Diseases, UMR 5293, F‐33000 Bordeaux, France, University of Bordeaux, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">France</country><wicri:regionArea>Institute of Neurodegenerative Diseases, UMR 5293, F‐33000 Bordeaux, France, National Center for Scientific Research, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Neurology</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="ISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><date type="published" when="2013-07">2013-07</date><biblScope unit="volume">74</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="140">140</biblScope><biblScope unit="page" to="144">144</biblScope></imprint><idno type="ISSN">0364-5134</idno></series><idno type="istex">83FE1078C36E1437D794AE68D5AEC6C76421ABFC</idno><idno type="DOI">10.1002/ana.23881</idno><idno type="ArticleID">ANA23881</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0364-5134</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenoviridae (genetics)</term><term>Adenoviridae (metabolism)</term><term>Animals</term><term>Antiparkinson Agents (pharmacology)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Conditioning, Operant (drug effects)</term><term>Conditioning, Operant (physiology)</term><term>Disease Models, Animal</term><term>Dopaminergic Neurons (drug effects)</term><term>Dopaminergic Neurons (pathology)</term><term>Food Preferences (drug effects)</term><term>Humans</term><term>Levodopa (pharmacology)</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Mutation (genetics)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (etiology)</term><term>Parkinson Disease (genetics)</term><term>Parkinson Disease (pathology)</term><term>Rats</term><term>Rats, Wistar</term><term>Reward</term><term>Saccharin (administration & dosage)</term><term>Substantia Nigra (pathology)</term><term>Sweetening Agents (administration & dosage)</term><term>Taste (drug effects)</term><term>Transduction, Genetic</term><term>Tyrosine 3-Monooxygenase (metabolism)</term><term>Ubiquitin (metabolism)</term><term>alpha-Synuclein (genetics)</term><term>alpha-Synuclein (toxicity)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Saccharin</term><term>Sweetening Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>alpha-Synuclein</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Tyrosine 3-Monooxygenase</term><term>Ubiquitin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Conditioning, Operant</term><term>Dopaminergic Neurons</term><term>Food Preferences</term><term>Taste</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Adenoviridae</term><term>Mutation</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Adenoviridae</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Dopaminergic Neurons</term><term>Parkinson Disease</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Conditioning, Operant</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="toxicity" xml:lang="en"><term>alpha-Synuclein</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Disease Models, Animal</term><term>Humans</term><term>Male</term><term>Rats</term><term>Rats, Wistar</term><term>Reward</term><term>Transduction, Genetic</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Dopamine dysregulation syndrome shares some core behavioral features with psychostimulant addiction, suggesting that dopamine replacement therapy can acquire psychostimulantlike properties in some patients with Parkinson disease (PD). We here report strong experimental evidence supporting this hypothesis in an α‐synuclein rat model of PD. Although levodopa had no effect in controls, it acquired 2 prominent psychostimulantlike properties in Parkinsonian rats: (1) it produced intense reward on its own and in parallel (2) decreased interest in other nondrug reward. These 2 effects may combine to explain the addictive use of levodopa after loss of midbrain dopamine neurons in some PD patients. Ann Neurol 2013;74:140–144</div></front></TEI><affiliations><list><country><li>Belgique</li><li>France</li><li>Italie</li></country><region><li>Aquitaine</li><li>Lombardie</li><li>Nouvelle-Aquitaine</li></region><settlement><li>Bordeaux</li><li>Milan</li></settlement></list><tree><country name="France"><region name="Nouvelle-Aquitaine"><name sortKey="Engeln, Michel" sort="Engeln, Michel" uniqKey="Engeln M" first="Michel" last="Engeln">Michel Engeln</name></region><name sortKey="Ahmed, Serge H" sort="Ahmed, Serge H" uniqKey="Ahmed S" first="Serge H." last="Ahmed">Serge H. Ahmed</name><name sortKey="Ahmed, Serge H" sort="Ahmed, Serge H" uniqKey="Ahmed S" first="Serge H." last="Ahmed">Serge H. Ahmed</name><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bezard">Erwan Bezard</name><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bezard">Erwan Bezard</name><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bezard">Erwan Bezard</name><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bezard">Erwan Bezard</name><name sortKey="Cador, Martine" sort="Cador, Martine" uniqKey="Cador M" first="Martine" last="Cador">Martine Cador</name><name sortKey="Cador, Martine" sort="Cador, Martine" uniqKey="Cador M" first="Martine" last="Cador">Martine Cador</name><name sortKey="Engeln, Michel" sort="Engeln, Michel" uniqKey="Engeln M" first="Michel" last="Engeln">Michel Engeln</name><name sortKey="Fernagut, Pierre Livier" sort="Fernagut, Pierre Livier" uniqKey="Fernagut P" first="Pierre-Olivier" last="Fernagut">Pierre-Olivier Fernagut</name><name sortKey="Fernagut, Pierre Livier" sort="Fernagut, Pierre Livier" uniqKey="Fernagut P" first="Pierre-Olivier" last="Fernagut">Pierre-Olivier Fernagut</name></country><country name="Italie"><region name="Lombardie"><name sortKey="Fasano, Stefania" sort="Fasano, Stefania" uniqKey="Fasano S" first="Stefania" last="Fasano">Stefania Fasano</name></region></country><country name="Belgique"><noRegion><name sortKey="Baekelandt, Veerle" sort="Baekelandt, Veerle" uniqKey="Baekelandt V" first="Veerle" last="Baekelandt">Veerle Baekelandt</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E64 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000E64 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:83FE1078C36E1437D794AE68D5AEC6C76421ABFC
|texte= Levodopa gains psychostimulant‐like properties after nigral dopaminergic loss
}}
| This area was generated with Dilib version V0.6.29. |  |